

PEER-REVIEW REPORT

Name of journal: World Journal of Surgical Procedures

Manuscript NO: 45382

Title: Can hyperthermic intraperitoneal chemotherapy effectively control gastric cancer-associated peritoneal carcinomatosis?

Reviewer's code: 02904061

Reviewer's country: China

Science editor: Li-Jun Cui

Date sent for review: 2019-02-14

Date reviewed: 2019-02-14

Review time: 4 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

1. There are several grammatical and spelling error in the abstract and throughout the manuscript suggesting the need for review by a native English speaker. 2. The manuscript should mention the recommend chemotherapeutic agents during HIPEC.



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

3. In the department of "A DEFINITIVE THERAPEUTIC MODALITY", study by Glehen et al showed that 5-year survival rate increased to 29.4%, while 5-year survival rate of other studies mentioned in the manuscript was only about 10%. 4. In the department of "A METHOD OF SYMPTOM PALLIATION", the authors should discuss the appropriate selection of patients for HIPEC to palliate ascites.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

REPLY TO EDITORS

1. There are several grammatical and spelling errors in the abstract and throughout the manuscript suggesting the need for review by a native English speaker.

Reply: The first draft of our manuscript has been reviewed by a native English speaker of "Wallace Academic Editing Company" (Certificate attached) before submission. This time, we also invited Professor Jhi-Joung Wang, a native American born Chinese who lived in the US for more than 30 years to revise our whole manuscript again. Thus, we added Jhi-Joung Wang as our co-author.

2. The manuscript should mention the recommended chemotherapeutic agents during HIPEC.

Reply: All chemotherapeutic agents mentioned in the manuscript have been described clearly in our revised manuscript.

3. In the department of "A DEFINITIVE THERAPEUTIC MODALITY", study by Glehen et al showed that 5-year survival rate increased to 29.4%, while 5-year survival rate of other studies mentioned in the manuscript was only about 10%.

Reply: The study by Glehen et al (2004) reported a better prognosis when compared with those by Yonemura et al (1996) and Sayag-Beaujard et al (1999). These better clinical outcomes demonstrated the significance of proper patient selection and technical progress in complete cytoreduction as experience increased. This explanation has been added in the main content of our revised manuscript.

4. In the department of "A METHOD OF SYMPTOM PALLIATION", the authors should discuss the appropriate selection of patients for HIPEC to palliate ascites.

Reply: For symptomatic patients with malignant ascites and complete cytoreduction deemed impossible, they should be selected to receive HIPEC to palliate ascites.

This explanation has been added in the main content of our revised manuscript.